Skip to main content
TipRanks
Go Ultimate75% OFF

Acadia Healthcare (7RA) AI Stock Analysis

0 Followers
DE:7RA

Acadia Healthcare

(XETRA:7RA)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Raised Earnings OutlookRepeated guidance increases indicate improving management confidence in the operating plan and earnings trajectory. The outlook combines higher revenue, EBITDA, adjusted EPS, and operating cash flow expectations, providing a durable foundation for execution over the next several quarters.
Negative Factors
Severe Profitability PressureThe sharp deterioration in net and gross margins indicates that revenue growth is not currently translating into comparable earnings strength. Persistent cost, pricing, or service-mix pressure could constrain reinvestment and make reported profitability volatile even as sales expand.

Acadia Healthcare (7RA) vs. iShares MSCI Germany ETF (EWG)

-50%0%50%100%150%200%DE:7RA+159.09%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 3.51B
Dividend Yield
―
Average Volume (3M)
94
Price to Earnings (P/E)
-3.0
Beta (1Y)
0.04
Revenue Growth
-0.56%
EPS Growth
-1113.32%
Country
Germany
Employees
22,000
Sector
Healthcare
Sector Strength
51
Industry
Medical - Care Facilities

Acadia Healthcare Business Overview & Revenue Model

Company Description

Acadia Healthcare Company, Inc. specializes in delivering a comprehensive range of behavioral health services, with its operations spanning the United States and Puerto Rico. Patients receive care in diverse environments, including acute inpatient ps...

Acadia Healthcare Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:17.12%|Next Earnings Date:Mar 01, 2027
Earnings Call SentimentPositive

The call was strongly positive. Acadia reported revenue, adjusted EBITDA, and adjusted EPS above expectations, generated $47 million of free cash flow, reduced debt by $63 million, raised full-year guidance for the third consecutive quarter, opened significant new capacity, and reported strong acute demand and improving CTC admissions. The main challenges were the New York Medicaid headwind, ongoing startup facility losses, flat sequential CTC revenue, lower commercial mix, shorter length of stay, and continued legal and revenue-cycle costs, but management described progress on each operational area and maintained a favorable outlook for 2027.

Positive Updates

Revenue and Same-Facility Growth Exceeded Expectations
Third-quarter revenue was $895 million, up 5.1% year over year. Same-facility revenue increased 5.2%, at the high end of expectations, driven by 1.1% growth in patient days and 4.0% growth in revenue per patient day.

Negative Updates

New York Medicaid Headwind
Changes in the New York Medicaid program affecting Pennsylvania facilities reduced third-quarter same-facility revenue growth by approximately 1% and same-facility volume growth by approximately 2.6%. Management said replacing the affected patients remains a work in progress.

Company Guidance

For 2026, Acadia raised guidance to revenue in a range of $3.44 billion-$3.46 billion, adjusted EBITDA in a range of $615 million-$625 million, adjusted EPS in a range of $1.70-$1.80, and operating cash flow in a range of $375 million-$400 million, while full-year CapEx is forecast in a range of $210 million-$230 million. The company expects approximately $60 million of incremental adjusted EBITDA from facilities opened in 2023, 2024, 2025, and 2026 in 2027 compared to 2026, supporting the previously discussed $200 million of incremental adjusted EBITDA relative to 2025; preliminary math projects startup facility losses declining from about $45 million to around $10 million, with break-even occupancy usually around 40%. Programs in Florida and Ohio could add more than $20 million in incremental EBITDA, but are not included in guidance ranges, and the company expects overall patient day growth to continue to be in that 3%-4% range.

Acadia Healthcare Risk Analysis

Acadia Healthcare disclosed 55 risk factors in its most recent earnings report. Acadia Healthcare reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Acadia Healthcare Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:7RA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HCSGHCSG78Outperform$1.68B16.4920.22%―3.96%175.90%
UHSUHS76Outperform$11.19B8.0519.54%0.41%8.00%13.14%
LFSTLFST72Outperform$5.35B74.034.82%―22.62%―
HCAHCA64Neutral$104.25B16.49-100.45%0.61%5.82%16.59%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
CYHCYH44Neutral$315.90M8.30-2.51%―-7.84%-88.93%

* Healthcare Sector Average

Performance Comparison

0%50%100%150%DE:7RACYHHCAHCSGUHSLFSTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:7RA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:7RAAcadia Healthcare Company, Inc.34.2020.60151.47%
CYHCommunity Health Systems2.24-0.77-25.58%
HCAHca Healthcare499.0525.195.32%
HCSGHealthcare Services Group24.907.8846.30%
UHSUniversal Health Services194.07-31.45-13.94%
LFSTLifestance Health Group, Inc.14.087.83125.28%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.